TNXP Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
EN
07/10/2020

Underlying

TNXPTonix Pharmaceuticals Holding Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tonix Pharmaceuticals Holding Corp

 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyc...

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite Treatment was well tolerated with minimal effects on weight or blood pressure CHATHAM, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- T...

January 30, 2026 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals to Present at Two Investor Conferences in Januar...

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor meetings at the following January 2026 investor conferences. Sachs Associates 9th Annual Neuroscience Innovation Forum Company Presentation Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals Date: Sunday, January 11, ...

January 6, 2026 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Di...

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase...

December 29, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Lon...

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia OspA mAb) available for clinical trials in early 2027 Approximately 70 million people that live, work or vacation in areas of the U.S. in which Lyme disease is endemic could potentially benefit from pre-exposure prophylaxis CHATH...

December 29, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-...

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling studies CHATHAM, N.J., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced licensing exclusive worldwide rights...

December 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch